Key result
Glycocalyx dietary supplement cuts perfused boundary region ~10% and lowers PWV vs placebo.
Why the study?
Does glycocalyx dietary supplement improve endothelial glycocalyx integrity and arterial stiffness in patients with psoriasis under biological agents?
RCT (n=50)
Randomly assigned
Does glycocalyx dietary supplement improve endothelial glycocalyx integrity and arterial stiffness in patients with psoriasis under biological agents?
Answers are grounded in this paper and cite their sources.
A 4-month treatment with a glycocalyx dietary supplement significantly improved endothelial glycocalyx integrity and reduced arterial stiffness in patients with psoriasis on biological agents.
Background Psoriasis predisposes to cardiovascular dysfunction. Purpose We investigated whether glycocalyx dietary supplement (GDS), which contains glycosaminoglycans and fucoidan, improves endothelial glycocalyx and arterial stiffness in psoriatic patients. Methods Fifty participants with psoriasis under biological agents were randomly assigned to GDS (n = 25) or placebo (n = 25) for 4 months. We measured at baseline and at follow-up: (a) perfused boundary region (PBR) of the sublingual microvessels (range 4 to 25 μm), a marker of endothelium glycocalyx integrity; (b) carotid–femoral pulse wave velocity (PWV-Complior SP-ALAM) and augmentation index (AIx), markers of arterial stiffness and (c) psoriasis area and severity index (PASI) score. Results Both groups displayed a similar decrease in PASI at four months (p < 0.05), and no significant differences were found between groups (p > 0.05). Compared to the placebo, participants in the GDS showed a greater percentage reduction in PBR4–25 μm (−9.95% vs. −0.87%), PBR 4–9 μm (−6.50% vs. −0.82%), PBR10–19 μm (−5.12% vs. −1.60%), PBR 20–25 μm (−14.9% vs. −0.31%), PWV (−15.27% vs. −4.04%) and AIx (−35.57% vs. −21.85%) (p < 0.05). In the GDS group, the percentage reduction in PBR 4–25 μm was associated with the corresponding decrease in PWV (r = 0.411, p = 0.015) and AΙx (r = 0.481, p = 0.010) at follow-up. Conclusion Four-month treatment with GDS improves glycocalyx integrity and arterial stiffness in patients with psoriasis.
No takes yet. Share an insight, caveat, or question.
Ikonomidis et al. (2025) conducted an RCT in Psoriasis (n=50). Glycocalyx dietary supplement (GDS) vs. Placebo was evaluated on Perfused boundary region (PBR) of the sublingual microvessels (range 4 to 25 μm) (p=<0.05). Four-month treatment with glycocalyx dietary supplement reduced perfused boundary region and pulse wave velocity compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: